Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

Next Previous
Search
Trial Profile

A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epoetin alfa (Primary) ; Iron sucrose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HOPE-Hb

    • Most Recent Events

    • 14 Jun 2021 Status changed from recruiting to discontinued with the primary reasoning that company was unable to demonstrate feasibility, prior to and because of the impact of COVID on their research programs.
    • 17 Sep 2019 Status changed from not yet recruiting to recruiting.
    • 02 Apr 2019 Planned initiation date changed from 1 Oct 2018 to 1 May 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top